TRIAL |
NAME |
ACTIVATION
DATE |
CURRENT
STATUS* |
CLOSURE
DATE |
TOTAL
# REGs |
| I1C | AT-125; colorectal | 81-NOV-03 | C |
82-MAY-31 | 20 |
| I2L | AT-125; NSCLC | 81-NOV-03 | C |
84-MAR-09 | 36 |
| I3 | Spirogerm; NHL | 83-FEB-09 | C |
84-MAY-14 | 18 |
| I4 | Lonidamine; renal | 82-APR-01 | C |
84-MAY-05 | 33 |
| I4B | Lonidamine; breast | 83-OCT-01 | C |
85-MAY-13 | 42 |
| I5 | Spirogerm; melanoma | 83-JUN-01 | C |
84-MAY-14 | 25 |
| I6 | Interferon; renal | 83-NOV-01 | C |
84-SEP-20 | 44 |
| I7 | Mitoxantrone; mesothelioma | 83-JUL-12 | C |
85-FEB-15 | 24 |
| I8 | NMF; colorectal | 84-DEC-14 | C |
85-APR-29 | 12 |
| I9 | TCAR; colorectal | 85-MAY-01 | C |
86-MAR-05 | 21 |
| I10 | TCAR; breast | | W |
| |
| I11 | TCAR; NSCLC | 85-MAY-01 | C |
87-MAR-01 | 16 |
| I12 | CBDCA; ovarian | 84-AUG-01 | C |
85-FEB-21 | 53 |
| I13 | NMF; glioma | 84-DEC-01 | C |
85-APR-29 | 3 |
| I14 | NMF; melanoma | 84-DEC-01 | C |
85-APR-29 | 12 |
| I15 | Mitoxantrone; sarcoma | 84-AUG-03 | C |
85-DEC-09 | 27 |
| I16 | AT-125; NHL | 84-NOV-12 | C |
87-OCT-30 | 13 |
| I17 | Acivicin/cisplatin; NSCLC | 85-MAR-01 | C |
88-APR-25 | 17 |
| I18 | Flutamide; breast | 85-MAR-27 | C |
86-MAR-01 | 35 |
| I19 | Menogaril; breast | 85-MAY-30 | C |
86-MAR-15 | 25 |
| I20 | Menogaril; lymphoma | 85-MAY-30 | C |
88-NOV-14 | 27 |
| I21 | Menogaril; melanoma | 85-MAY-30 | C |
86-MAR-15 | 21 |
| I22 | 2' DCF; HC leukemia | 85-APR-26 | C |
86-JUL-15 | 31 |
| I23 | Acivicin; colorectal | 85-SEP-17 | C |
86-APR-28 | 27 |
| I24 | 2' DCF; renal | 85-SEP-06 | C |
86-NOV-26 | 20 |
| I25 | Trimetrexate; ovarian | 86-JUL-28 | C |
88-MAY-02 | 18 |
| I26 | Trimetrexate; melanoma | 86-JUL-28 | C |
87-NOV-06 | 19 |
| I27 | Trimetrexate; glioma | 86-JUL-28 | C |
88-MAR-14 | 15 |
| I28 | Trimetrexate; sarcoma | 86-JUL-28 | C |
87-DEC-31 | 28 |
| I28A | Trimetrexate; sarcoma | 88-JAN-25 | C |
89-JAN-09 | 27 |
| I29 | Adriamycin/Ifosfamide/DTIC; sarcoma | 86-JAN-21 | C |
87-NOV-03 | 43 |
| I30 | VP-16+DDP; mesothelioma | 86-JAN-09 | C |
87-APR-01 | 30 |
| I31 | VP-16+CBDCA; SCLC | 85-DEC-18 | C |
86-OCT-09 | 37 |
| I32 | Trimetrexate; phase I | 85-APR-01 | C |
85-DEC-01 | 15 |
| I33 | Epirubicin; SCLC | 86-APR-29 | C |
87-JUL-31 | 41 |
| I34 | IFN levamisole; melanoma; phase I | 86-NOV-13 | C |
87-MAY-07 | 10 |
| I35 | Lonidamine; breast | 86-DEC-08 | C |
88-JAN-08 | 4 |
| I36 | Didemnin-B; phase I | 86-NOV-01 | C |
91-NOV-29 | 53 |
| I37 | Flavone acetic acid; melanoma | | W |
| |
| I38 | TNF; renal | 88-JUN-01 | C |
89-SEP-01 | 26 |
| I39 | TNF; melanoma | | W |
| |
| I40 | TNF; colorectal | | W |
| |
| I41 | Hexamethylmelamine; SCLC | | W |
| |
| I42 | IV amonafide; SCLC | 87-OCT-23 | C |
88-APR-25 | 13 |
| I43 | DUP-937; phase I | 88-AUG-19 | C |
90-AUG-10 | 32 |
| I44 | DUP-937; phase I | 88-AUG-18 | C |
91-MAR-11 | 33 |
| I45 | Menogaril; breast | 89-AUG-27 | C |
90-APR-15 | 53 |
| I46 | Sulofenur; renal | 89-OCT-25 | C |
90-MAY-11 | 19 |
| I47 | Sulofenur; SCLC | 89-OCT-25 | C |
90-NOV-30 | 12 |
| I48 | PCV-3; oligodendroglioma | 89-FEB-06 | C |
92-SEP-02 | 33 |
| I49 | Gemcitabine; renal | 90-MAR-19 | C |
90-NOV-30 | 18 |
| I50 | Gemcitabine; SCLC | 91-FEB-04 | C |
92-SEP-29 | 29 |
| I51 | GMCSF+Carboplatin; ovarian; phase I | 89-MAY-29 | C |
90-FEB-10 | 15 |
| I51A | GMCSF+Carboplatin; ovarian; phase I | 90-FEB-10 | C |
90-SEP-28 | 7 |
| I52 | GM-CSF; SCLC; phase I | 89-NOV-06 | C |
90-SEP-19 | 6 |
| I53 | Anagrelide; thrombocythemia | | W |
| |
| I54 | Tiazofurin; glioma | 90-APR-18 | C |
91-MAY-28 | 18 |
| I55 | 10-EDAM; sarcoma | 90-SEP-04 | C |
92-MAR-06 | 32 |
| I56 | DUP-937; melanoma | 91-MAR-07 | C |
92-APR-23 | 16 |
| I57 | DUP-937; NSCLC | 91-APR-04 | C |
92-APR-02 | 16 |
| I58 | DUP-937; colorectal | 91-APR-04 | C |
91-NOV-10 | 17 |
| I59 | IL-3+Carboplatin; phase I | 90-DEC-10 | C |
92-MAR-27 | 17 |
| I60 | 10-EDAM; breast | 90-OCT-29 | C |
91-SEP-17 | 35 |
| I61 | 10-EDAM; melanoma | 91-JAN-08 | C |
92-JAN-21 | 16 |
| I62 | IL-2+IFN alpha; myeloma | 91-OCT-07 | C |
93-FEB-17 | 17 |
| I63 | Vinorelbine; renal | | W |
| |
| I64 | Vinorelbine; melanoma | | W |
| |
| I65 | Elsamitrucin; NSCLC | 92-JUN-01 | C |
92-DEC-04 | 17 |
| I66 | 13 cis-retinoic/IFN alpha; NSCLC | 92-JUN-15 | C |
93-MAY-28 | 34 |
| I67 | Fostriecin; phase I | 92-SEP-10 | C |
96-MAY-21 | 46 |
| I68 | Taxotere; breast | 92-JUN-01 | C |
93-JUN-30 | 51 |
| I69 | Taxotere; SCLC | 93-FEB-08 | C |
93-OCT-18 | 14 |
| I70 | Taxotere; renal | 92-AUG-24 | C |
93-FEB-03 | 20 |
| I71 | Topotecan; sarcoma | 92-JUN-08 | C |
94-FEB-04 | 32 |
| I72 | Sandostatin; colorectal | | W |
| |
| I73 | Mifepristone; breast | 92-APR-27 | C |
95-FEB-28 | 28 |
| I74 | Cisplatin/Taxol; ovarian; phase I | 92-NOV-02 | C |
94-OCT-07 | 29 |
| I75 | Topotecan; glioma | 92-SEP-08 | C |
94-JAN-25 | 31 |
| I76 | Taxotere; glioma | 94-APR-04 | C |
95-APR-28 | 18 |
| I77 | Taxotere; sarcoma | 94-MAR-28 | C |
95-JUN-30 | 32 |
| I78 | Didemnin B; lymphoma | 93-SEP-01 | C |
94-OCT-25 | 10 |
| I79 | Taxol/Ifosfamide; NSCLC; phase I | 93-SEP-13 | C |
96-FEB-08 | 68 |
| I80 | Taxol/radiation; NSCLC; phase I | 94-MAR-14 | C |
96-JUN-14 | 17 |
| I81 | Tallimustine; SCLC | 94-AUG-16 | C |
95-JUN-14 | 16 |
| I82 | Topotecan; ovarian; rand. phase II | 94-JUL-08 | C |
97-APR-22 | 104 |
| I83 | Arotinoid+Tamoxifen; breast | | W |
| |
| I84 | Topotecan+VP16; relapsed AML; phase I | 94-DEC-07 | C |
95-NOV-23 | 11 |
| I85 | JM216/oral VP16; phase I | 94-AUG-22 | C |
94-NOV-08 | 6 |
| I86 | 9-aminocamptothecin CD; phase I | 95-FEB-13 | C |
96-OCT-28 | 20 |
| I87 | High dose levamisole; melanoma; phase Ib | 95-JUN-26 | C |
97-MAY-01 | 28 |
| I88 | 9-cis-retinoic acid/INF alpha; renal; phase I/II | 95-AUG-03 | C |
97-APR-29 | 38 |
| I89 | LY231514; NSCLC | 95-SEP-12 | C |
97-FEB-04 | 33 |
| I90 | LY231514; colorectal | 95-SEP-12 | C |
96-JUN-21 | 33 |
| I91 | BB2516; melanoma | 95-AUG-01 | C |
97-MAR-31 | 29 |
| I92 | 9-aminocamptothecin;14 day cont. inf. q28d;phaseI | | W |
| |
| I93 | Amifostine/Paclitaxel; breast; randomized | 96-APR-24 | C |
98-SEP-24 | 50 |
| I94 | Gemcitabine; malignant glioma | 96-MAY-06 | C |
97-APR-28 | 20 |
| I95 | Gemcitabine/Cisplatin; bladder | 96-AUG-06 | C |
97-OCT-03 | 33 |
| I96 | JM216+VP16; phase I | 96-JUL-15 | C |
99-JUN-03 | 33 |
| I97 | DPPE/Adriamycin; breast | 96-MAY-10 | C |
98-JAN-06 | 42 |
| I98 | Tomudex/Doxorubicin; gastric; phase I | 96-OCT-24 | C |
99-APR-07 | 25 |
| I99 | Topotecan; lymphoma | | W |
| |
| I100 | Topotecan & etoposide; AML | 96-OCT-09 | C |
98-MAY-13 | 26 |
| I101 | RPR 109881A; phase I | 96-SEP-23 | C |
98-MAR-13 | 29 |
| I102 | JM216; cervix | 97-JAN-27 | C |
99-FEB-16 | 18 |
| I103 | BCH4556; phase I | 97-JAN-27 | C |
99-MAR-02 | 45 |
| I104 | Bryostatin 1; melanoma (rand. phase II) | 97-JUN-05 | C |
98-OCT-26 | 34 |
| I105 | 776C85 + 5FU; head & neck | 97-FEB-10 | C |
99-FEB-22 | 32 |
| I106 | Topotecan/cisplatin/paclitaxel; ovarian | 97-JUN-10 | C |
98-MAY-07 | 44 |
| I106B | Topotecan/cisplatin/paclitaxel/carboplatin;ovarian | 99-APR-27 | C |
99-DEC-16 | 13 |
| I107 | BAY 12-9566; phase I | 97-JAN-27 | C |
97-DEC-10 | 29 |
| I108 | Topotecan & etoposide; non-Hodgkin's lymphoma | 97-JUN-05 | C |
98-MAY-07 | 23 |
| I109 | Topotecan; oligodendroglioma | 97-DEC-08 | C |
00-APR-20 | 17 |
| I110 | LY231514/CDDP; NSCLC | 98-APR-15 | C |
99-JUN-07 | 32 |
| I111 | 3521/5132; prostate; rand. phase II | 98-FEB-12 | C |
99-JAN-22 | 31 |
| I112 | 3521/5132; colorectal; rand. phase II | 98-MAR-11 | C |
99-SEP-29 | 38 |
| I113 | BAY 12-9566/5FU/Doxorubicin; phase I | 98-FEB-10 | C |
99-SEP-20 | 31 |
| I114 | SR49059; SCLC | 99-APR-05 | C |
00-OCT-20 | 7 |
| I115 | Aplidine; phase I | 99-FEB-15 | C |
02-FEB-07 | 37 |
| I116 | 5132; ovary | 99-FEB-01 | C |
00-MAY-05 | 22 |
| I117 | ET 743; renal | | W |
| |
| I118 | ET 743; ovary | | W |
| |
| I119 | BCH 4556; renal | 99-JUN-16 | C |
00-MAR-21 | 35 |
| I120 | BCH 4556; NSCLC | 99-JUN-16 | C |
00-MAY-30 | 18 |
| I121 | LY335979 + vinorelbine; phase I | 99-MAR-01 | C |
00-NOV-06 | 21 |
| I122 | ZD 1839; phase I | 99-JUN-14 | C |
01-JUN-28 | 56 |
| I123 | NX-211; phase I | 99-FEB-25 | C |
00-JUN-09 | 37 |
| I124 | MG-98; 21 day infusion; phase I | 99-FEB-11 | C |
00-MAY-12 | 14 |
| I125 | MG-98; twice weekly; phase I | 99-FEB-22 | C |
01-MAR-08 | 19 |
| I126 | Letrozole endometrium | 00-JAN-19 | C |
01-MAY-16 | 33 |
| I127 | Flavopiridol; mantle cell lymphoma | 00-JAN-24 | C |
01-OCT-10 | 33 |
| I128 | SCH66336; bladder | 99-DEC-03 | C |
01-MAY-01 | 20 |
| I129 | ZD0473; breast | 00-JAN-14 | C |
01-MAR-02 | 33 |
| I130 | T900607; phase I | 00-APR-07 | C |
02-DEC-19 | 30 |
| I131 | ZD0473 & docetaxel; phase I | 00-MAY-04 | C |
02-FEB-08 | 33 |
| I132 | Temozolomide; breast | 00-AUG-01 | C |
01-SEP-26 | 19 |
| I133 | NX211 & cisplatin; phase I | 00-MAR-22 | C |
01-NOV-22 | 14 |
| I133B | NX211 & cisplatin; phase I | | W |
| |
| I134 | BAY 38-3441; phase I | 00-MAY-12 | C |
03-JAN-16 | 34 |
| I135 | COT; phase I | 00-JUN-28 | C |
02-FEB-07 | 31 |
| I136 | Flavopiridol; sarcoma | 00-JUL-04 | C |
01-MAR-06 | 18 |
| I137 | Flavopiridol; melanoma | 00-JUL-04 | C |
01-JUL-13 | 17 |
| I138 | NX211; ovary; rand. phase II | 00-OCT-31 | C |
01-SEP-21 | 81 |
| I139 | T138067; glioma | 00-NOV-08 | C |
02-JAN-09 | 19 |
| I140 | ZD1839; prostate; rand. phase II | 01-APR-24 | C |
02-APR-25 | 40 |
| I141 | BAY 43-9006;myelodysplasia & leuk; rand.phase I | 01-OCT-01 | C |
04-APR-01 | 42 |
| I142 | SarCNU; glioma | 02-JAN-10 | C |
02-DEC-17 | 10 |
| I143 | MG98; renal cell carcinoma | 01-MAY-01 | C |
02-MAY-10 | 19 |
| I144 | LY293111; phase I | 01-MAR-23 | C |
04-JUN-29 | 29 |
| I145 | ZD6474; multiple myeloma | 02-OCT-02 | C |
04-APR-08 | 18 |
| I146 | SarCNU; colorectal | 01-OCT-30 | C |
03-AUG-14 | 18 |
| I147 | OSI-7836; phase I | 01-SEP-28 | C |
04-FEB-17 | 27 |
| I148 | OSI-774; endometrium | 02-JAN-10 | C |
04-MAR-16 | 34 |
| I149 | OSI-774 & carboplatin; ovary | 02-JAN-10 | C |
04-JUN-01 | 50 |
| I150 | PS341; mantle cell lymphoma | 02-JUL-04 | C |
04-JUL-28 | 30 |
| I151 | LY317615 & carbo/taxol; phase I | | W |
| |
| I152 | PS341; Waldenstrom's Macroglobulinemia | 02-AUG-27 | C |
05-MAR-23 | 27 |
| I153 | OGX; prostate; phase I | 02-DEC-06 | C |
04-MAY-05 | 25 |
| I154 | OGX + docetaxel; phase I | 03-MAR-06 | C |
05-JUN-28 | 40 |
| I155 | perifosine; sarcoma | 03-MAY-15 | C |
04-AUG-10 | 17 |
| I156 | perifosine; melanoma | 03-MAY-16 | C |
04-APR-26 | 18 |
| I157 | OSI-774 & cisplatin, head and neck | 03-FEB-10 | C |
04-SEP-22 | 14 |
| I158 | ALVAC; melanoma; phase I | | W |
| |
| I159 | ALVAC; melanoma | | W |
| |
| I160 | CCI-779; endometrium | 04-JAN-14 | C |
07-JUN-15 | 62 |
| I161 | Triapine; RCC | 04-JAN-16 | C |
05-APR-05 | 19 |
| I162 | RAD001C; glioma; phase I | 06-JUL-25 | C |
09-JUN-01 | 32 |
| I163 | RAD001C; breast | 05-JAN-19 | C |
07-JAN-11 | 49 |
| I164 | OGX-011 & docetaxel, advanced breast | 05-JUN-27 | C |
06-SEP-29 | 15 |
| I165 | OGX-011 & docetaxel, prostate | 05-JUN-27 | C |
06-DEC-21 | 82 |
| I166 | AEG35156 & docetaxel; phase I | 05-APR-04 | C |
06-JUL-10 | 10 |
| I166B | AEG35156 & docetaxel; phase I | 06-JUN-20 | C |
08-MAR-20 | 27 |
| I167 | BAY 43-9006; prostate | 04-JUN-21 | C |
05-DEC-20 | 28 |
| I168 | SB-715992; hepatocellular carcinoma | 04-NOV-24 | C |
06-MAY-04 | 15 |
| I169 | SB-715992; malignant melanoma | 04-NOV-22 | C |
06-MAY-01 | 17 |
| I170 | GW572016; malignant glioma; phase I/II | 04-DEC-16 | C |
07-MAY-08 | 24 |
| I171 | AZD2171; NSCLC or colorectal; phase I | 05-JAN-13 | C |
09-FEB-17 | 50 |
| I172 | Bortezomib & gemcitabine; mantle cell lymphoma | 06-JUN-14 | C |
08-SEP-19 | 29 |
| I173 | AZD5030 & gemcitabine; pancreatic; phase I/II | 05-JUL-19 | C |
08-MAY-29 | 34 |
| I174 | BMS-275183; NSCLC | | W |
| |
| I175 | AZD2171; advanced NSCLC or colorectal cancer; phase I | 05-AUG-08 | C |
07-MAR-30 | 31 |
| I176 | GeminX; SCLC | | W |
| |
| I177 | AT7519M; phase I | 06-AUG-22 | C |
11-APR-04 | 34 |
| I178 | JX-963 plus GM-CSF; solid tumours; phase I | | W |
11-APR-29 | |
| I179 | CCI-779 with carboplatin & paclitaxel; phase I | 06-OCT-25 | C |
09-MAR-27 | 39 |
| I180 | AMG-706, cisplatin & etoposide; NSCLC; phase I/II | | W |
| |
| I181 | AT9283; advanced incurable malignancy; phase I | 07-JAN-04 | C |
09-NOV-24 | 35 |
| I182 | Sunitinib (SU11248); large B-cell lymphoma | 06-NOV-08 | C |
09-MAR-24 | 19 |
| I183 | Sunitinib (SU11248); pleural mesothelioma | 06-NOV-10 | C |
10-SEP-10 | 39 |
| I184 | Sunitinib (SU11248); cervical carcinoma | 06-NOV-09 | C |
08-MAY-12 | 19 |
| I185 | Sunitinib (SU11248); ovarian, fallopian tube | 06-NOV-10 | C |
08-APR-17 | 31 |
| I186 | BAY 43-9006 & cytarabine; AML/high risk MDS; phase I/II | 07-JUL-24 | C |
09-DEC-10 | 21 |
| I187 | AZD2281 & irinotecan; colorectal; phase I | 07-AUG-13 | C |
12-MAR-08 | 26 |
| I188 | SB939; advanced cancer; phase I | 07-JUN-21 | C |
10-MAR-16 | 39 |
| I189 | rIL-21; metastatic or recurrent melanoma | 07-JUL-10 | C |
09-AUG-17 | 40 |
| I190 | MK-0646 IGFR; small cell lung; phase I/II | 09-JAN-30 | C |
11-MAR-10 | 12 |
| I191 | AKI AT 9283; multiple myeloma | 10-JUN-15 | C |
12-JUL-26 | 8 |
| I192 | Deforolimus; endometrial | 08-AUG-26 | C |
10-AUG-11 | 35 |
| I193 | AT7519M; Lymphocytic; phase II | 12-JUN-21 | C |
13-NOV-22 | 7 |
| I194 | AT7519M; Lymphoma; phase II | 12-JUL-24 | C |
14-MAY-07 | 12 |
| I195 | SB939; Prostate; phase II | 10-FEB-10 | C |
11-NOV-04 | 32 |
| I196 | GSK1363089+erlotinib; NSCLC; phase I/II | 09-DEC-17 | C |
13-JAN-24 | 31 |
| I197 | GSK1363089; Breast; phase II | 10-MAY-25 | C |
13-AUG-02 | 47 |
| I198 | GSK1363089 and trastuzumab/lapatinib; Breast; phase I/II | 10-JUN-03 | C |
13-MAR-05 | 19 |
| I199 | CCI779; Cervix; phase II | 09-DEC-17 | C |
11-OCT-27 | 38 |
| I200 | SB393; Sarcoma; phase II | 10-MAR-18 | C |
12-JAN-25 | 24 |
| I201 | 43162 | | W |
| |
| I202 | IL21; Melanoma; phase II | 10-JUN-28 | C |
12-FEB-29 | 64 |
| I203 | SB939; Pediatric; phase I | 10-SEP-21 | C |
12-JAN-25 | 12 |
| I204 | PX-866; Glioma; phase II | 10-DEC-09 | C |
12-SEP-24 | 34 |
| I205 | PX-866; CRPC; phase II | 11-APR-04 | C |
14-JAN-10 | 68 |
| I206 | Sunitinib/Temsirolimus; Rare tumours; phase II | 11-JUL-14 | C |
15-FEB-05 | 137 |
| I207 | PF-03446962; Mesothelioma; phase II | 11-NOV-30 | C |
14-JAN-09 | 17 |
| I208 | BKM120 + Panitumumab; Colorectal Cancer; phase I/II | 12-MAY-01 | C |
15-JUL-14 | 22 |
| I209 | Reolysin +/- Docetaxel/Prednisone;Prostate;PhII | 12-JUN-11 | C |
15-SEP-25 | 85 |
| I210 | Reolysin + FOLFOX6/bevacizumab; Colorectal; PhII | 12-JUN-11 | C |
15-FEB-12 | 109 |
| I211 | Reolysin + Docetaxel/Pemetrexed; NSCLC, Phase II | 12-OCT-15 | C |
15-AUG-06 | 166 |
| I212 | Imetelstat alone or with 13-cis-retinoic, Pediatric, Phase I | 13-JUL-30 | C |
13-NOV-22 | |
| I213 | Reolysin + Pacitaxel, Breast, Phase II | 12-JUL-30 | C |
16-APR-20 | 81 |
| I214 | MG1MA3 with or without ADVAC/MA3; Colorectal/NSCLC; Ph I/II | 14-OCT-31 | C |
19-APR-11 | 56 |
| I215 | Selumetinib; NSCLC; Phase Ib | 13-JAN-30 | C |
15-OCT-16 | 39 |
| I216 | | 15-JAN-30 | C |
17-JAN-24 | 14 |
| I217 | | 14-NOV-03 | C |
19-APR-18 | 30 |
| I218 | | 15-JUN-02 | C |
17-MAR-31 | 7 |
| I219 | | 15-FEB-05 | C |
17-MAY-08 | 62 |
| I220 | | | W |
| |
| I221 | | 15-AUG-24 | C |
17-APR-20 | 59 |
| I222 | | 16-JAN-13 | C |
18-OCT-19 | 15 |
| I223 | | 17-FEB-09 | C |
21-DEC-13 | 19 |
| I224 | | 16-NOV-23 | C |
19-APR-24 | 6 |
| I225 | | 16-MAY-12 | C |
18-MAR-12 | 9 |
| I226 | | 15-OCT-01 | C |
17-SEP-06 | 153 |
| I228 | | 16-OCT-19 | C |
20-JAN-21 | 140 |
| I229 | | 16-APR-21 | C |
17-APR-20 | 15 |
| I230 | | | W |
| |
| I231 | | 16-MAY-16 | C |
19-NOV-25 | 41 |
| I232 | | 16-AUG-18 | C |
19-OCT-01 | 52 |
| I233 | | | W |
| |
| I234 | | 17-DEC-12 | C |
24-FEB-27 | 200 |
| I234A | | 17-DEC-12 | C |
21-DEC-08 | |
| I234B | | 17-DEC-12 | C |
24-FEB-27 | |
| I234C | | 17-DEC-12 | C |
24-FEB-27 | |
| I234D | | 19-MAR-18 | C |
22-DEC-20 | |
| I234E | | 19-DEC-27 | C |
24-FEB-27 | |
| I234F | | 19-DEC-27 | C |
24-FEB-27 | |
| I234G | | 20-JUN-10 | C |
24-FEB-27 | |
| I235 | | 18-AUG-28 | C |
19-AUG-02 | 4 |
| I236 | | 18-OCT-17 | C |
22-APR-07 | 37 |
| I237 | | 18-DEC-21 | C |
23-JAN-17 | 51 |
| I238 | | 19-JUN-07 | O |
| |
| I238B | | 22-APR-14 | O |
| |
| I239 | | 19-DEC-19 | C |
22-APR-26 | 15 |
| I240 | | 21-OCT-12 | O |
| |
| I240A | | 21-OCT-12 | O |
| |
| I240B | | 21-OCT-12 | O |
| |
| I241 | | 23-JAN-27 | O |
| |
| I241A | | 23-JAN-27 | O |
| |
| I241B | | 23-JAN-27 | O |
| |
| I241C | | 23-JAN-27 | O |
| |
| I241E | | | W |
| |
| I242 | | 23-MAY-26 | O |
| |
| I242A | | 23-MAY-26 | O |
| |
| I243 | | 23-APR-17 | O |
| |
| I244 | | 23-OCT-24 | O |
| |
